According to a new report from Bloomberg, Mylan NV has a new plan to further ubiquitize its cash cow EpiPen: cut out pharmacies as the middleman and sell the drug directly to public places.

Utilizing a similar strategy to its push to get EpiPens stocked in schools nationwide, Mylan is intensely lobbying state officials around the country to approve legislation allowing "entity prescriptions." No state allowed these sales prior to Mylan's push — now more than 30 are on board.

Why it matters: Mylan's idea has the potential to revolutionize how medicines, especially those that might be needed in a public space, are sold. At the expense of traditional pharmacies, buying EpiPens directly from Mylan would cut the product's price by more than half for the consumer, while still allowing Mylan to make the same profit.

Go deeper

16 mins ago - World

Nuclear free-for-all: The arms control era may be ending

Illustration: Aïda Amer/Axios

The mushroom clouds over Hiroshima and Nagasaki have remained unreplicated for 75 years in part because the U.S. and Soviet Union — after peering over the ledge into nuclear armageddon — began to negotiate.

Why it matters: The arms control era that began after the Cuban Missile Crisis may now be coming to a close. The next phase could be a nuclear free-for-all.

Pelosi, Schumer demand postmaster general reverse USPS cuts ahead of election

Schumer and Pelosi. Photo: Alex Wong/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Minority Leader Chuck Schumer sent a letter to Postmaster General Louis DeJoy on Thursday calling for the recent Trump appointee to reverse operational changes to the U.S. Postal Service that "threaten the timely delivery of mail" ahead of the 2020 election.

Why it matters: U.S. mail and election infrastructure are facing a test like no other this November, with a record-breaking number of mail-in ballots expected as Americans attempt to vote in the midst of a pandemic.

2 hours ago - Science

CRISPR co-discoverer on the gene editor's pandemic push

Photo illustration: Aïda Amer/Axios. Photos: Brian Ach/Getty Images for Wired and BSIP/UIG via Getty Images

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease — and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR — which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing — are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.